表4　証拠のレベル

証拠レベル	主たる研究方法	内容
1++	無作為化比較対照試験	死亡率減少効果の有無を示す，質の高い無作為化比較対照試験が行われている
	系統的総括	死亡率減少効果の有無を示す，質の高いメタアナリシスなどの系統的総括が行われている
1+	無作為化比較対照試験	死亡率減少効果の有無を示す，中等度の質の無作為化比較対照試験が行われている
	系統的総括	死亡率減少効果の有無を示す，中等度の質のメタアナリシスなどの系統的総括が行われている
	ＡＦ組み合わせ	Analytic Frameworkの重要な段階において無作為化比較対照試験が行われており，2++以上の症例対照研究・コホート研究が行われ，死亡率減少効果が示唆される
1−	無作為化比較対照試験	死亡率減少効果に関する質の低い無作為化比較対照試験が行われている
	系統的総括	死亡率減少効果に関するメタアナリシスなどの系統的総括が行われているが質が低い
2++	症例対照研究/コホート研究	死亡率減少効果の有無を示す，質が高い症例対照研究・コホート研究が行われている
2+	症例対照研究/コホート研究	死亡率減少効果の有無を示す，中等度の質の症例対照研究・コホート研究が行われている
	ＡＦ組み合わせ	死亡率減少効果の有無を示す直接的な証拠はないが，Analytic Frameworkの重要な段階において無作為化比較対照試験が行われており，一連の研究の組み合わせにより死亡率減少効果が示唆される
2−	症例対照研究/コホート研究	死亡率減少効果に関する，質の低い症例対照研究・コホート研究が行われている
	ＡＦ組み合わせ	死亡率減少効果の有無を示す直接的な証拠はないが，Analytic Frameworkを構成する複数の研究がある
3	その他の研究	横断的な研究，発見率の報告，症例報告など，散発的な報告のみでAnalytic Frameworkを構成する評価が不可能である
4	専門家の意見	専門家の意見

AF: Analytic Framework
注1）研究の質については，以下のように定義する
　質の高い研究：バイアスや交絡因子の制御が十分配慮されている研究．
　中等度の質の研究：バイアスや交絡因子の制御が相応に配慮されている．
　質の低い研究：バイアスや交絡因子の制御が不十分である研究．
（厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班 主任研究者 祖父江友孝，有効性評価に基づくがん検診ガイドライン作成手順）

について対比し，さらに両者の評価から，推奨のレベル（表5）を決定する．系統的総括の結果に基づき，各検診方法の死亡率減少効果と不利益に関する科学的根拠を明確にし，わが国における対策型検診と任意型検診の実施について，推奨として総括する．定式化された作成手順に基づき，大腸がん検診の推奨は表6として評価された[9]．

諸外国におけるがん検診ガイドラインと比較すると，無作為化比較対照試験により死亡率減少効果が示されている便潜血検査化学法は，いずれのガイドラインの評価も高い[9]．ただし，便潜血検査免疫法を評価対象としているのは，米国のACS（American Cancer Society）とAGA（American College of Gastroenterology）のガイドラインに限られる．S状結腸鏡検査は，USPTF，CTFPHC（Canadian Task Force on Preventive Health Care）だけでなく，米国諸学会でも推奨されているが，フィンランドでは推奨していない．一方，便潜血検査化学法との併用法は，CTFPHCでは効果不明と判定している．S状結腸鏡検査を推奨している米国ACSのガイドラインでは，単独・併用法ともに受診間隔を5年としている．一方，全大腸内視鏡検査は，主として米国における臨床ガイドラインで推奨されており，受診間隔は10年としている．

表5　推奨のレベル

推奨	表現	対策型検診（住民検診型）	任意型検診（人間ドック型）	証拠のレベル
A	死亡率減少効果を示す十分な証拠があるので，実施することを強く勧める．	推奨する	推奨する	1++/1+
B	死亡率減少効果を示す相応な証拠があるので，実施することを勧める．	推奨する	推奨する	2++/2+
C	死亡率減少効果を示す証拠があるが，無視できない不利益があるため，対策型検診として実施することは勧められない． 任意型検診として実施する場合には，安全性を確保し，不利益に関する説明を十分に行い，受診するかどうかを個人が判断できる場合に限り，実施することができる	推奨しない	条件付きで実施できる	1++/1+/2++/2+
D	死亡率減少効果がないことを示す証拠があるため，実施すべきではない．	推奨しない	推奨しない	1++/1+/2++/2+
I	死亡率減少効果の有無を判断する証拠が不十分であるため，対策型検診として実施することは勧められない．任意型検診として実施する場合には，効果が不明であることと不利益について十分説明する必要がある．その説明に基づく，個人の判断による受診は妨げない．	推奨しない	個人の判断に基づく受診は妨げない	1−/2−/3/4

注1）　対策型検診は，公共的な予防対策として，地域住民や職域などの特定の集団を対象としている．
その目的は，集団におけるがんの死亡率を減少させることである．
対策型検診は，死亡率減少効果が科学的に証明されていること，不利益を可能な限り最小化することが原則となる．
具体的には，市町村が行う老人保健事業による住民を対象としたがん検診や職域において法定健診に付加して行われるがん検診が該当する．

注2）　任意型検診とは，医療機関や検診機関が任意で提供する保健医療サービスである．
その目的は，個人のがん死亡リスクを減少させることである．
がん検診の提供者は，死亡率減少効果の明らかになった検査方法を選択することが望ましい．
がん検診の提供者は，対策型検診では推奨されていない方法を用いる場合には，
死亡率減少効果が証明されていないこと，および，当該検診による不利益について十分説明する責任を有する．
具体的には，検診センターや医療機関などで行われている総合健診や人間ドックなどに含まれているがん検診が該当する．

注3）　推奨Iと判定された検診の実施は，有効性評価を目的とした研究を行う場合に限定することが望ましい．

（厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班 主任研究者 祖父江友孝．有効性評価に基づくがん検診ガイドライン作成手順）

表6　大腸がん検診の推奨レベル

検診方法	証拠のレベル	推奨レベル	内容	対策型検診	任意型検診
便潜血検査化学法	1++	A	死亡率減少効果を示す十分な証拠がある	○	○
便潜血検査免疫法	1+	A	死亡率減少効果を示す十分な証拠があるが，	○	○
S状結腸鏡検査	1+	C	死亡率減少効果を示す十分な証拠があるが，無視できない不利益がある 安全性を確保し，受診者へ十分な説明を行ったうえで，実施することができる	×	○
S状結腸鏡検査と便潜血検査化学法の併用法	2+	C	死亡率減少効果を示す十分な証拠があるが，無視できない不利益がある 安全性を確保し，受診者へ十分な説明を行ったうえで，実施することができる	×	○
全大腸内視鏡検査	2+	C	死亡率減少効果を示す相応な証拠があるが，無視できない不利益がある 安全性を確保し，受診者へ十分な説明を行ったうえで，実施することができる	×	○
注腸X線検査	2+	C	死亡率減少効果を示す相応な証拠があるが，無視できない不利益がある 安全性を確保し，受診者へ十分な説明を行ったうえで，実施することができる	×	○
直腸指診	2+	D	死亡率減少効果を示す証拠がない	×	×

（厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班主任研究者 祖父江友孝．有効性評価に基づく大腸がん検診ガイドライン）

4．精度管理

がん検診の精度管理については，関連学会が技術的管理を中心としたガイドラインなどを公表している．老人保健事業については，各都道府県の成人病検診管理指導協議会がその任に当たっている[10]が，一部を除いて十分な機能を果たしていない．市町村についても，対象者の把握と管理，記録の整備，発見がんの追跡調査などが求められている[10]．このため，「医療・介護関係事業者における個人情報の適切な取り扱いのためのガイドライン」では，公衆衛生上の目的として，医療機関の精密検査結果の情報提供は，本人同意がなくても行える例外事項に含まれている[11]．

精度管理指標の設定には，対象となる集団の死亡率が理想的であるが，通常は，代替的指標として，がん発見率，要精検率，早期がん割合などが用いられる．わが国においては，厚生労働省がん検診検討会において，乳がん・子宮がん検診の見直しに関する中間報告において，精度管理システムのチェックリストが公表されている[12]．一方，ECでは，乳がん検診の精度管理のガイドラインを作成し，精度管理指標となる，がん発見率，要精検率などについて，一定の目標値を定めている[13]．今後の精度管理のためには，プロセス管理・アウトカム管理に基づくシステムの構築が課題である．

■文献

1) 厚生労働省大臣官房統計情報部(編)：平成4年～15年度地域保健・老人保健事業報告(老人保健編) 1993-2004，厚生統計協会，東京
2) Center for Disease Control and Prevention : Behavioral Risk Factor Survey. Atlanta, A : National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 2002
3) NHS Health and Social Care Information Centre, Community Health Statistics. Breast Screening Program, England : 2004-2005, 2006
4) NHS Health and Social Care Information Centre, Community Health Statistics. Cervical Screening Program, England : 2004-2005, 2006
5) 深尾 彰，濱島ちさと，祖父江友孝ほか：有効性評価に基づく胃がん検診ガイドライン(普及版)．癌と化学療法（印刷中）
6) Miles A, Cockburn J, Smith RA et al : A prospective from countries using organized screening programs. Cancer **101** (S5) : 1201-1213, 2004
7) 平成12年度厚生労働省老人保健事業推進費等補助金　がん検診の適正化に関する調査研究事業，新たながん検診手法の有効性評価報告書（主任研究者：久道茂），公衆衛生協会，2001
8) 祖父江友孝，濱島ちさと，齋藤博ほか：有効性評価に基づくガイドライン作成手順(普及版)．癌と化学療法 **32** ： 893-900，2005
9) 祖父江友孝，濱島ちさと，齋藤 博ほか：有効性評価に基づく大腸がん検診ガイドライン(普及版)．癌と化学療法 **32** ： 901-915，2005
10) 厚生省老人保健福祉局老人保健課(監)：老人保健法による健康診査マニュアル，日本医事新報社，東京，1998
11) 厚生労働省：医療・介護関係事業者における個人情報の適切な取り扱いのためのガイドライン，2003
12) 厚生労働省がん検診に関する検討会：老人保健事業に基づく乳がん及び子宮がん検診における事業評価の手法について：中間報告，2005
13) The European Community Guideline for Quality Assurance in Mammography Screening. Luxemburg. Europe Against Cancer Programmed, Office for Official Publications of the European Communities, 2001

Journal of Digestive Diseases 2007; 8; 8–14 doi: 10.1111/j.1443-9573.2007.00278.x

Using serum pepsinogens wisely in a clinical practice

Kazumasa MIKI* & Yoshihisa URITA†

*Division of Gastroenterology and Hepatology, Department of Internal Medicine (Ohmori) and †General Medicine and Emergency Care, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

Serum pepsinogen (PG) has been used as biomarkers of gastric inflammation and mucosal status, including atrophic change, before the discovery of *Helicobacter pylori* (*H. pylori*). Serum pepsinogen I (PG I) and pepsinogen II (PG II) levels are known to increase in the presence of *H. pylori*-related nonatrophic chronic gastritis. The measurement of serum PG provides much information on the presence of intestinal metaplasia as well as atrophic gastritis. The eradication of *H. pylori* provokes a significant change in serum PG values: it reduces both PG I and PG II and elevates the PG I to PG II ratio. Recently, the serum PG test method has been the first screening step in Japan, as well as photofluorography. Serum PG tests are used to screen for high risk subjects with atrophic gastritis, rather than as a test for cancer itself. Unlike photofluorography or endoscopy, serum PG screening can identify non-ulcerated differentiated asymptomatic cancer, irrespective of the size and location of the lesion. Most cases detected by the PG method are asymptomatic early gastric cancers and are limited to the mucosa, which are particularly well suited for endoscopic treatment. The PG method can contribute greatly to the patients' quality of life.

KEY WORDS: atrophic gastritis, gastric cancer screening, non-atrophic gastritis, serum pepsinogens I and II.

INTRODUCTION

Serum PG is classified into two biochemically and immunologically distinct types, namely, PGI and PG II (PG I is also called PGA, and PG II is also called PGC). PG I is produced by chief and mucous neck cells in the fundic glands, while PG II is produced by these cells and also by the cells in the pyloric glands and Brunner's glands.[1–3] It is widely accepted that serum PG levels reflect the functional and morphologic status of stomach mucosa. As the fundic gland mucosa reduces, PG I levels gradually decrease, whereas PG II levels remain fairly constant.[4–6] As a result, a stepwise reduction of the PG I/II ratio is closely correlated with the progression from normal gastric mucosa to extensive atrophic gastritis.

Correspondence to: Kazumasa MIKI, Division of Gastroenterology and Hepatology, Department of Internal Medicine (Ohmori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Ohmori-Nishi, Ota-Ku, 143-8541, Tokyo, Japan. Email: mikik@med.toho-u.ac.jp

Serum PG has been used as a biomarker of gastric mucosal status, including atrophic change and inflammation, before the discovery of *Helicobacter pylori* (*H. pylori*). *H. pylori* are now recognized as the main acquired factor in the pathogenesis of peptic ulcer disease and chronic gastritis. The potential mechanisms by which *H. pylori* induces mucosal damage include injury to gastric cells by direct contact of the bacterium through elaboration of enzymes and putative cytotoxins, immune response, and effects of *H. pylori* on the mechanisms that control gastric secretion.[7] Since these changes in gastric secretion affect the serum PG levels, subjects should be divided into two groups according to their *H. pylori* status. Thus, the interpretation of serum PG has changed remarkably since the discovery of *H. pylori*. In this review we reflect on the relevant physiology behind the measurement of serum PG and discuss the relevant literature concerning their use.

GASTRIC ACID SECRETION

There is a close association between the level of gastric acid secretion and the type of disease affecting the

gastrointestinal tract. Gastro-esophageal reflux disease and duodenal ulcers are likely to occur in patients with high levels of acid secretion,[8,9] whereas gastric ulcers are more likely in patients with moderately reduced secretion.[10] Patients with gastric cancer also have profoundly reduced or absent acid secretion.[11,12]

Patients with duodenal ulcers have increased PG I levels, which were believed to be of genetic origin.[13] Several studies have demonstrated a significant association between serum PG I and gastric secretion,[14–16] whereas a few studies did not show any significant relation.[17] Iijima *et al.*[18] examined the correlation between PG I and maximal acid output and concluded that PG I is influenced not only by parietal cell mass but also by gastric mucosal inflammation induced largely by *H. pylori* infection, which could be responsible for its good correlation with acid secretion in *H. pylori*-infected patients. In using serum PG as a marker of gastric acid secretion, it is necessary to take into account for the *H. pylori* status of the patient.

H. PYLORI INFECTION

H. pylori infection is now accepted as the major cause of chronic gastritis and atrophic gastritis is the most common cause of reduced gastric acid secretion.[19,20] Serum PG I and PG II levels are known to increase in the presence of *H. pylori*-related nonatrophic chronic gastritis. In particular, PG II was reported to exhibit a greater rise relative to PG I.[21,22] There was little correlation between PG II and gastric acid secretion because of the wide variety of PG II levels in *H. pylori*-positive subjects.[14] In contrast, in *H. pylori*-negative subjects, PG II is a relatively constant value and correlates with acid secretion, since PG II is derived from both the pyloric gland and the fundic gland.

It is well known that serum PG levels in patients with duodenal ulcers are higher than those observed in *H. pylori* gastritis,[23,24] and increased PG I was believed to be of genetic origin.[13] However, increased PG I levels decrease after *H. pylori* eradication.[23,25,26] Cave *et al.*[27] showed that *H. pylori* sonicate and *H. pylori* lipopolysaccharide stimulate PG release from isolated rabbit gastric glands. This suggests a direct stimulatory effect of *H. pylori* on chief cells. Young *et al.*[28] also showed that purified *H. pylori* lipopolysaccharide increased PG secretion 50-fold while the *E coli* lipopolysaccharide raised this secretion only 12-fold. It was reported that there was no differences in PG secretion between cagA-positive and -negative strains,[29] suggesting that other factors must be involved.

The eradication of *H pylori* decreases the severity of gastritis and provokes a significant change in serum PG values: it reduces both PG I and PG II and elevates the PG I to PG II ratio.[21,30] To decide whether *H. pylori* has been completely eradicated it is necessary to prove the disappearance of the organisms after eradication therapy. It is sometimes difficult to decide this based on bacterial examinations such as culture tests, histology, and the urease test on endoscopy, because of decreased bacterial density or changes of the organism.[31] Di Mario *et al.*[32] demonstrated that optimal cut-off values to evaluate the success of therapy were: a PG II of 9.47 mg/L, a PG II variation level (the difference between the baseline and after therapy) of 4.54 mg/L, and a PG II delta value (the PG II variation divided by the PG II before therapy of 25% (sensitivity 93%, specificity 91%). Gisbert *et al.*[33] also reported that *H. pylori* eradication was associated with a significant decrease in basal PG II levels that is detected immediately (one month) after completing the treatment. However, the decrease in PG I level occurs progressively for 6 months. They concluded that the measurement of PG I concentration has a limited usefulness in the diagnosis of *H. pylori* reinfection after successful eradication, although PG II determination could be more useful in this situation. Furuta *et al.*[34] determined the optimal cut-off values for percentage changes in serum PG I/PG II ratios. The values were tentatively set as +40%, +25%, and +10% when the serum PG I/PG II ratios before treatment were less than 3.0, not less than 3.0 but less than 5.0, and not less than 5.0, respectively. The serum PG method has an advantage because as no endoscopy is required, repeated examinations will be accepted by patients. Thus, the serological method may be a useful non-invasive method for determining the eradication of *H. pylori*.

ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA

The clinical importance of atrophic gastritis with intestinal metaplasia is related to the fact that it increases the risk of gastric cancer development.[35–37] In the process of carcinogenesis, at least for intestinal types of gastric carcinomas, it was proposed that the gastric mucosa evolves through the stages of chronic active gastritis, glandular atrophy, intestinal metaplasia, and dysplasia before developing into gastric adenocarcinoma.[17] The risk of gastric neoplasia rises with the increasing grade and extent of atrophic gastritis.[38] Atrophic gastritis is usually diagnosed with endoscopy and biopsies. However, there is a significant potential sampling error in identifying intestinal metaplasia by a random biopsy because the intestinal metaplasia of the gastric mucosa was reported to be patchy.

It is now clear that intestinal metaplasia is a part of the spectrum of atrophic gastritis with *H. pylori* infection. Xia *et al.*[39] showed that the prevalence of intestinal metaplasia was significantly higher at the gastric antrum of the patients with an *H. pylori* infection compared with uninfected subjects. However, only some of the infected patients go on to develop intestinal metaplasia, suggesting that factors other than *H. pylori*, such as environmental and host genetic factors, may contribute to the progression from atrophic gastritis to intestinal metaplasia. In our previous study,[40] the overall prevalence of intestinal metaplasia was 52% (455/878) and it was higher in subjects with lower PG I/II ratios and lower PG I values. Intestinal metaplasia was found in 252 (82%) of 299 subjects with a PG I/II ratio of less than 2.5 and in 58 (88%) of 66 subjects with a PG I value of less than 25 ng/mL. Thus, it is potentially possible that serum PG is used as a screening test for high risk subjects with atrophic gastritis and intestinal metaplasia. The measurement of serum PG provides much information on the presence of intestinal metaplasia as well as atrophic gastritis.

In Japan, several studies[22,37] have shown that the prevalence of infection is strongly associated with age and this age-related increase in infection falls in the elderly. Thus, the absence of serum antibodies in patients with active or previous infection seems to increase in the elderly.[41,42] It is possible that patients who had a previous infection and do not have serum antibodies are not detected as a high risk group for gastric cancer, despite the presence of severe atrophic gastritis. Measuring serum PG can detect patients with extensive atrophic gastritis, regardless of their *H. pylori* status.

GASTRIC CANCER SCREENING

Recently, the serum PG method has become the first screening step in Japan, instead of photofluorography,[43–46] because several problems in the latter method have been noted, such as its cost-effectiveness, the risks to those screened of X-ray exposure, and the low sensitivity of photofluorography (less than 40%) in detecting early gastric cancer.[46] The serum PG method has made it possible to screen large populations without the need for endoscopy. Serum PG, especially PG I and PG I/II ratio, have been proven to be markers for atrophic gastritis.[47–49] Therefore, the measurement of serum PG has recently drawn attention as a candidate for a new screening test for gastric cancer in Japan.[43–45]

Cut-off point of pepsinogen

Although several determinations of a suitable cut-off point for gastric cancer screening have previously been reported, using a serum PG I concentration of less than 70 ng/mL and a PG I/II ratio of less than 3.0 as the cut-off point has been widely accepted in Japan.[43,45]

Dinis-Ribeiro *et al.*[50] demonstrated the validity of the PG test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. Forty-two data sets were analyzed: 27 population-based screening studies (n = 296 553) and 15 sets of selected individuals (n = 4385). Pooled pairs of sensitivity and false positive rates (Fpr) for PG I ≤70; PG I/II ratio ≤3.0, for PG I ≤50; PG I/II ratio ≤3.0, and for PG I ≤30; PG I/II ratio ≤2.0, were sensitivity 77%/Fpr 27%, sensitivity 68%/Fpr 31%, and sensitivity 52%/Fpr 84%, respectively. Positive predictive values varied between 0.77% and 1.25%, and negative predictive values varied between 99.1% and 99.9%. Kitahara *et al.*[45] report a sensitivity of 84.6% and a positive predictive value of 0.81% with a cut-off point of PG I ≤70 and PG I/II ratio ≤3.0. Miki *et al.*[47] also used the same cut-off point and showed a sensitivity of 96.0% and a positive predictive value of 1.3%. When using a low cut-off point of PG I ≤50, the sensitivity and the positive predictive value were reduced to 68% and 0.7%, respectively. Hattori *et al.*[51] reported a sensitivity of 66.7% and a positive predictive value of 1.3% with a cut-off point of PG I ≤50 and PG I/II ratio ≤3.0.

Comparison to X-ray method

In Japan, mass-screening programs for gastric cancer by indirect roentogenography are widely used, because gastric cancers are potentially curable if they are diagnosed at early stages, unlike cancers of the lung, liver, and pancreas. In fact, the 5-year survival rate of gastric cancer in Osaka, Japan, where gastric cancer screening is conducted, is 34.1%,[52] a much higher proportion than that in Detroit, where its screening has not been promoted.[53] Since most patients with abdominal symptoms can easily go to the hospital where a further examination by endoscopy or roentogenography can be done, it is likely that patients with the advanced cancer are not included in gastric cancer screening. Consequently, the proportion of early gastric cancer becomes larger in a Japanese screening test. In fact, a number of studies have reported that screen-detected gastric cancers showed an earlier stage distribution and had a lower case fatality rate than symptom-diagnosed cases. The proportion of early gastric cancer among screen-detected cases is 15–30% higher than among symptom-diagnosed cases.[54] Besides, the sensitivity of the X-ray method has been found to be less than 40% in detecting early gastric cancer and greater than 90% in detecting advanced gastric cancer.[16] Thus the

sensitivity of PG screening for gastric cancer seems superior to that of X-ray method when based on the results of endoscopic examination.

According to the standardized procedure proposed by the Japanese Society of Gastroenterological Mass Survey, seven consecutive photofluorograms, covering the whole area of the stomach, are taken for each screened individual, using roll films that are 100 mm in width. Trained radiographic technicians take the photofluorogram and two gastroenterologists examine the films. A screened individual with a suspected abnormality is referred for further diagnostic examinations, including endoscopy and a full-size radiography. Although the sensitivity (66.1–90.1%) and specificity (77.2–92.0%) of X-ray method showed an acceptable accuracy,[55–57] the identification of false negative cases is a critical part of quantifying these indices. If the photofluorography with direct radiography is used for gastric cancer screening, or if more than seven photofluorograms are taken, false negative cases might decrease.

On the other hand, we have to consider the false-negative rate in evaluation of the screening method. Were there any cases in which the X-ray methods were suggestive but the PG levels were not? I have been very anxious on this point. We previously reported the lower detection rate of gastric cancer in the elderly.[5] In this previous study, the percentage of cancers detected by the PG method was similar (0.15% in subjects less than 40 years of age; 0.14% in those 60 or older), whereas those by the X-ray method were 0.01% in those less than 40-years old and 0.23% in those aged 60 or older. This suggested that some of the older patients with gastric cancer might be missed by the PG method. As suggested by a referee of this article, it is almost certain that there would be some cancer patients with negative results using the PG method who were detected by the X-ray method.

In subjects with mild atrophy, gastric cancer originating in the pyloric gland region is difficult to detect by the PG method. Similarly, in the small type cancer, as the cancer was limited to a small part of the fundic gland area, the serum PG I level and PG I/II ratio were only slightly decreased. The PG method is used as a screening test for high risk subjects with atrophic gastritis, rather than as a test for cancer itself, and thus there is a possibility that the PG method might miss cancer patients without atrophic gastritis.

Comparison to endoscopy

Endoscopic screening is highly effective for gastric cancer, but it is relatively expensive. However, in the absence of screening, patients present with advanced disease, and their prognosis is poor. There is a nation-wide program for the detection of gastric cancer in Chile using screening endoscopy in symptomatic patients.[58] Before these screening programs, only 40% of patients who were found to have gastric cancer could be treated surgically, and there was only a 3% 5-year survival rate. After the induction of endoscopic screening programs, there has been a 75% 5-year survival rate because they have markedly increased the number of early gastric cancers. Dan *et al.*[59] also reported the validity of endoscopic screening for gastric cancer in China. The screening of their cohort of 199 000 subjects prevented 743 gastric cancer deaths and saved 8234 absolute life years. The cost of averting one cancer death is $US 247 600. They conclude that screening of a high risk group of Chinese men from 50- to 70-years old is highly cost effective. Although certain lesions are difficult to detect by the X-ray method; for example, small or flat lesions and even large lesions located in the cardia or on the anterior wall, such cancers can be easily detected by endoscopy. However, who should pay for asymptomatic screening examinations?

On the other hand, the problem of false negatives has been unclear. Hosokawa *et al.*[60] reported a false-negative rate of 22.2% when a new gastric cancer lesion was detected within 3 years by follow-up endoscopy. Nishizawa *et al.*[61] also demonstrated that 6 gastric cancers which were discovered in subjects with a previous definition of normal in a follow-up survey, were advanced. Although endoscopic screening is highly effective, it does not have a sensitivity of 100% and may result in incidental diseases, including endoscopy-related infections such as viral hepatitis or *H. pylori*. It goes without saying that the screening method should avoid such complications during the procedure.

Advantages and disadvantages of serum pepsinogen method

Although a gastric cancer screening system using a double contrast barium X-ray was introduced in the 1960s throughout Japan, 49 213 people died from gastric cancer in 2002.[62] This suggests that the screening program is unable to cover a small proportion of the high risk population[63] and only a small proportion of people screened positive by serum PG are also given positive results by photofluorography.[64] The test performed for the first time in a population would detect prevalent cases at relatively advanced stages, while the test conducted subsequently in the same population would detect cases at less advanced stages occurring during the screening intervals.[65] Therefore, a test that is

highly sensitive for the initial prevalent screening may be less so for subsequent incident screenings.[51] Although the serum PG method has been criticized for its relatively low specificity, by using it we would avoid missing gastric cancer in a mass screening.

Serum PG is used as a screening test for high risk subjects with atrophic gastritis rather than as a test for cancer itself. However, unlike photofluorography or endoscopy, serum PG screening can identify non-ulcerated differentiated asymptomatic cancer, irrespective of the size and location of the lesion. Ohata *et al.*[66] reported that cases detected only by the PG method were all asymptomatic early gastric cancers and 89% were limited to the mucosa, and thus are particularly well suited for endoscopic treatment. This suggests that the PG method can contribute greatly to patients' quality of life by detecting cancer in its early stages. On the other hand, in subjects with mild atrophic gastritis, gastric cancer originating in the pyloric gland region, including in an advanced stage, is difficult to detect by the PG method. Therefore, symptomatic subjects or PG method-negative subjects should be screened by a barium X-ray examination instead of endoscopy. The serological examination of *H. pylori* antibody is additional alternative to the X-ray. *H. pylori* are recognized as one of the possible causes of gastric carcinoma. Kikuchi *et al.*[67] reported that among subjects younger than 40 years old, early stage carcinoma has a stronger association with *H. pylori* than advanced carcinoma, and intestinal- and diffuse-type carcinomas have an association with *H. pylori*. It has been demonstrated that the percentages of those with severe serological atrophy increased with age from 10% in those aged 40–49 years to 38% in those aged 70 and more, and the percentages of those with mild serological atrophy were about 30%, independent of age.[68] Although the prevalence of *H. pylori* infection in Japan has fallen in recent years,[22] those who are infected remain at risk of gastric cancer. An *H. pylori* infection was detected in up to 70% of the population by the age of 40 years in Japan.[22] Since early life acquisition of *H. pylori* has been considered to increase the risk of developing gastric cancer,[69] infected individuals aged 40–50 years (belonging to the age group with the largest number of people in Japan), will be at higher risk of gastric cancer in the near future.

Despite the world decline in incidence and mortality, gastric cancer is a leading cause of cancer death in many countries.[70] The high prevalence of intestinal metaplasia among *H. pylori* infected patients suggests that the risk of developing gastric cancer will continue to remain high. Since gastric cancers are potentially curable if they are diagnosed at the early stages, it is insufficient to check the *H. pylori* antibody alone to detect subjects with severe atrophic gastritis. The PG test method is needed for *H. pylori*-positive subjects. Conversely, low-risk subjects who do not have atrophic gastritis or *H. pylori* infection can be detected by the combined screening method using the PG test and *H. pylori* serology. We have to make a further study to determine whether subjects with low-risk for gastric cancer can skip an annual screening.

REFERENCES

1 Huang SC, Miki K, Sano J *et al.* Pepsinogens I and II in gastric cancer: an immunohistochemical study using monoclonal antibodies. *Jpn J Cancer Res* 1988; 79: 1139–46.
2 Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. *Gastroenterology* 1971; 61: 185–8.
3 Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. *Gastroenterology* 1973; 65: 36–42.
4 Miki K, Ichinose M, Shimizu A *et al.* Serum pepsinogens as a screening test of extensive chronic gastritis. *Gastroenterol Jpn* 1987; 22: 133–41.
5 Miki K, Ichinose M, Ishikawa KB *et al.* Clinical application of serum pepsingen I and II levels for mass screening to detect gastric cancers. *Jpn J Cancer Res* 1993; 84: 1086–90.
6 Ichinose M, Yahagi N, Oka M *et al.* Screening for gastric cancer in Japan. In: Wu GY, Aziz K, eds. *Cancer Screening Practical Guide for Physicians*. Totowa, NY: Humana Press, 2001, pp. 255–68.
7 Calam J, Gibbons A, Healey ZV *et al.* How does *Helicobacter pylori* cause mucosal damage? Its effect on acid and gastrin physiology. *Gastroenterology* 1997; 113 (Suppl.): S43–9.
8 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. *Gastroenterology* 1990; 98: 654–61.
9 Zhu H, Pace F, Sangaletti O *et al.* Gastric acid secretion and pattern of gastroesophageal reflux in patients with esophagitis and concomitant duodenal ulcer. A multivariate analysis of pathogenetic factors. *Scand J Gastroenterol* 1993, 28: 387–92.
10 Carlborg L, Dahlgren S, Nordgren B. Gastric secretion of hydrochloric acid and sialic acid in patients with peptic ulcer and gastric cancer during intravenous infusion of histamine. *Scand J Gastroenterol* 1970; 5: 427–31.
11 Kobayashi S, Kizu M, Kasugai T. Gastric acid secretion in relation to gross type of gastric cancer. *Am J Gastroenterol* 1973; 60: 366–71.
12 Konturek SJ, Starzynska T, Konturek PC *et al.* *Helicobacter pylori* and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. *Scand J Gastroenterol* 2002, 37: 891–8.
13 Samloff IM, Liebman WM, Panitch NM. Serum group I pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer. *Gastroenterology* 1975; 69: 83–90.
14 Feldman M, Richardson CT, Lam SK *et al.* Comparison of gastric acid secretion rates and serum pepsinogen 1 and 2 concentrations in accidental and oriental duodenal ulcer patients. *Gastroenterology* 1998, 95: 630–5.
15 Haruma K, Yoshihara M, Sumii K *et al.* Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid type early gastric carcinoma. *Scand J Gastroenterol* 1993, 28: 633–7.

16 Kinoshita Y, Kawanami C, Kishi K *et al*. *Helicobacter pylori*-independent chronological change in gastric acid secretion in the Japanese. *Gut* 1997; 41: 452–8.
17 Yasunaga Y, Shinomura Y, Kanayama S *et al*. Serum pepsinogen 1 levels and acid secretion in *Helicobacter pylori* associated enlarged fold gastritis. *Int J Gastroenterol* 1995; 28: 457–61.
18 Iijima K, Sekine H, Koike T *et al*. Serum pepsinogen concentrations as a measure of gastric acid secretion in *Helicobacter pylori*-negative and -positive Japanese subjects. *J Gastroenterol* 2005; 40: 938–44.
19 Dooley CP, Cohen H, Fitzgibbsons PL *et al*. Prevalence of *Helicobacter pylori* infection and histologic gastritis in asymptomatic persons. *N Engl J Med* 1989; 321: 1562–6.
20 Graham DY. *Campylobacter pylori* and peptic ulcer disease. *Gastroenterology* 1989; 96 (Suppl.): 615–25.
21 Wagner S, Haruma K, Gladziwa U *et al*. *Helicobacter pylori* infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. *Am J Gastroenterol* 1994; 89: 1211–8.
22 Asaka M, Kimura T, Kudo M *et al*. Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic Japanese population. *Gastroenterology* 1992; 102: 760–6.
23 Chen TS, Lee YC, Li FY *et al*. Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in *Helicobacter pylori*-infected patients. *J Clin Gastroenterol* 2005; 39: 699–703.
24 Biasco G, Paganelli GM, Varia D *et al*. Serum pepsinogen 1 and 2 concentrations and IgG antibody to *Helicobacter pylori* in dyspeptic patients. *J Clin Pathol* 1993; 46: 826–8.
25 Kuipers EJ, Pals G, Pena AS *et al*. *Helicobacter pylori*, pepsinogens and gastrin: relationship with age and development of atrophic gastritis. *Eur J Gastroenterol Hepatol* 1996; 8: 133–6.
26 Hunter FM, Correa P, Fonthan E *et al*. Serum pepsinogens as markers of response to therapy for *Helicobacter pylori* gastritis. *Dig Dis Sci* 1993; 38: 81–6.
27 Cave TR, Cave DR. *Helicobacter pylori* stimulates pepsin secretion from isolated rabbit gastric glands. *Scand J Gastroenterol* 1991; 181: 9–14.
28 Young GO, Stemmet N, Fastovica A *et al*. *Helicobacter pylori* lipopolysaccharide stimulates gastric mucosal pepsinogen secretion. *Aliment Pharmacol Ther* 1992; 6: 169–77.
29 Lorente S, Diaz O, Serrano MT *et al*. *Helicobacter pylori* stimulates pepsinogen secretion from isolated human peptic cells. *Gut* 2002; 50: 13–8.
30 Ohkusa T, Takashimizu I, Fujiki K *et al*. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in *Helicobacter pylori*-positive gastric ulcer after eradication of infection. *J Clin Gastroenterol* 1997; 25: 317–22.
31 Rauws EAJ, Langenberg W, Houthoff HJ *et al*. *Campylobacter pylori*-associated chronic active gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment. *Gastroenterology* 1988; 94: 33–40.
32 Di Mario F, Moussa AM, Cavallaro LG *et al*. Clinical usefulness of serum pepsinogen 2 in the management of *Helicobacter pylori* infection. *Digestion* 2004; 70: 167–72.
33 Gisbert JP, Boixeda D, Al-Mostafa A *et al*. Basal and stimulated gastrin and pepsinogen levels after eradication of *Helicobacter pylori*: a 1-year follow-up study. *Eur J Gastroenterol Hepatol* 1999; 11: 189–200.
34 Furuta T, Kaneko E, Baba S *et al*. Percentage changes in serum pepsinogens are useful as indices of eradication of *Helicobacter pylori*. *Am J Gastroenterol* 1997; 92: 84–8.
35 Muñoz SS. The etiology of gastric cancer. *J Natl Cancer Inst* 1983; 71: 629–47.
36 Komoto K, Haruma K, Kamada T *et al*. *Helicobacter pylori* infection and gastric neoplasia: correlations with histological gastritis and tumor histology. *Am J Gastroenterol* 1998; 93: 1271–6.
37 Correa P. *Helicobacter pylori* and gastric carcinogenesis. *Am J Surg Pathol* 1995; 19: S37–S43.
38 Sipponen P, Kekki M, Haapakoski J *et al*. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer* 1985; 35: 173–7.
39 Xia HHX, Kalantar JS, Talley NJ *et al*. Antral-type mucosa in the gastric incisura, body, and fundus (antralization): a link between *Helicobacter pylori* infection and intestinal metaplasia? *Am J Gastroenterol* 2000; 95: 114–21.
40 Hirta Y, Hike K, Torii N *et al*. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. *Dig Dis Sci* 2001; 49: 795–801.
41 Shirin H, Brück R, Kenet G *et al*. Evaluation of a new immunochromatographic test for *Helicobacter pylori* IgG antibodies in elderly symptomatic patients. *J Gastroenterol* 1999; 34: 7–10.
42 Newell DG, Hawtin PR, Stacey AR *et al*. Estimation of prevalence of *H. pylori* infection in an asymptomatic elderly population comparing [^{14}C] urea breath test and serology. *J Clin Pathol* 1991; 44: 385–7.
43 Miki K, Ichinose M, Kakei N *et al*. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. In: Takahashi K, ed. *Aspartic Proteinases: Structure, Function, Biology and Biomedical Implications*. New York: Plenum Press, 1995; 139–43.
44 Kodori A, Yoshihisa M, Sumi K *et al*. Serum pepsinogen in screening for gastric cancer. *J Gastroenterol* 1995; 30: 452–60.
45 Kitahara F, Kobayashi K, Sato T *et al*. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. *Gut* 1999; 44: 693–7.
46 Nishizawa Y. Investigation of mass survey for gastric cancer. *J Gastroenterol Mass Survey* 1993; 98: 74–9 (in Japanese).
47 Miki K. Gastric cancer screening using serum tests (stomach dry dock). Study of the systems of the first screening for cancer-susceptible subjects by serum pepsinogen levels and the secondary close-examination by every-other year panendoscopy. *J Gastroenterol Mass Survey* 1994; 32: 19–30 (in Japanese).
48 Oksanen A, Sipponen P, Miettinen A *et al*. Evaluation of blood tests to predict normal gastric mucosa. *Scand J Gastroenterol* 2000; 35: 791–5.
49 Biemond I, Kreuning J, Jansen JB *et al*. Serum pepsinogens in patients with gastric diseases or after gastric surgery. *Scand J Gastroenterol* 1994; 29: 238–42.
50 Dinis-Ribeiro M, Yamaki G, Miki K *et al*. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen* 2004; 11: 141–7.
51 Hattori Y, Tashiro H, Kawamoto T *et al*. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. *Jpn J Cancer Res* 1995; 86: 1210–5.
52 Hanai A, Tsukuma H, Hiyama T *et al*. Cancer survival in Osaka. In: Tominaga S, Aoki K, Fujimoto I *et al*., eds. *Cancer Mortality and Morbidity Statistics*. Ann Arbor, MI: CRC Press, 1991; 159–65.
53 Gorey KM, Holowaty EJ, Fehringer G *et al*. An international comparison of cancer survival: Toronto, Ontario, and Detroit, Michigan, metropolitan areas. *Am J Public Health* 1997; 87: 1156–63.
54 Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. *Gastric Cancer* 2000; 3: 9–18.

55 Murakami R, Tsukuma H, Ubukata T *et al* Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. *Cancer* 1990; 65: 1255–60.
56 Fukao A, Hisamichi S, Takano A *et al* Accuracies of mass screening for gastric cancer-test sensitivity and program sensitivity. *J Gastroenterol Mass Survey* 1992; 97: 59–63. (in Japanese).
57 Hosakawa O. Transition in the diagnostic methods for gastric cancer and screening for gastric cancer. *J Gastroenterol Mass Survey* 1995; 33: 195–9 (in Japanese)
58 Waye JD, Abakken L, Armengol-Miro JR *et al.* Screening for GI cancer and payment mechanisms. *Gastrointest Endosc* 2002; 55. 453–4.
59 Dan YY, So BJ, Yeoh KG. Endoscopic screening for gastric cancer. *Clin Gastroenterol Hepatol* 2006; 4: 709–16.
60 Hosokawa O, Hattori M, Takeda T *et al* Accuracy of endoscopy in detecting gastric cancer. *Jpn J Gastroenterol Mass Survey* 2004; 42: 33–9 (in Japanese).
61 Nishizawa M, Nomoto K, Hosoi T *et al.* The diagnostic precision of routine panendoscopy in the detection of early cancer of the stomach. *J to Cho* 1985; 20: 949–54 (in Japanese)
62 Ministry of Health, Labour and Welfare. *Vital Statistics of Japan, Statistics and Information*, vol. 1. Tokyo: Minister's Secretariat, Ministry of Health, Labour and Welfare, 2002 (in Japanese)
63 Koga M, Miyakawa K, Ikeda S *Annual Report of Gastroenterological Mass Survey in Japan, 2002*. Tokyo: Japanese Society of Gastroenterology Mass Survey, 2004 (in Japanese).
64 Yoshihara M, Sumii K, Haruma K *et al.* The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. *Hiroshima J Med Sci* 1997; 46: 81–6.
65 Morrison AS *Screening in Chronic Disease*, 2nd edn New York Oxford University Press, 1992.
66 Ohata H, Oka M, Yanaoka K *et al.* Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. *Cancer Sci* 2005; 96: 713–20
67 Kikuchi S, Wada O, Nakajima T *et al.* Serum anti-*Helicobacter pylori* antibody and gastric carcinoma among young adults Research Group on Prevention of Gastric Carcinoma among Young Adults. *Cancer* 1995; 75: 2789–93.
68 Kikuchi S, Yagyu K, Obata Y *et al* Serum pepsinogen values and *Helicobacter pylori* status among control subjects of a nested case-control study in the JACC study. *J Epidemiol* 2005; 15 (Suppl.): S126–33
69 Blaser MJ, Chyou PH, Nomura A. Age at establishment of *Helicobacter pylori* infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. *Cancer Res* 1995; 55 562–5
70 Parkin DM, Pisani P, Ferlay J Estimates of the worldwide incidence of 25 major caners in 1990. *Int J Cancer* 1999; 80: 827–41

Inflammopharmacology 15 (2007) 1–5

DOI 10.1007/s10787-007-0895-z

Inflammopharmacology

Review

Salivary gland scintigraphy in gastro-esophageal reflux disease

Y. Urita[1,*], K. Domon, T. Yanagisawa, S. Ishihara[2], M. Hoshina[1], T. Akimoto, H. Kato, N. Hara, Y. Honda, Y. Nagai, K. Nakanishi, N. Shimada, M. Takano[3], S. Hayashi, M. Sugimoto[1], K. Miki[4]

[1] Department of General Medicine and Emergency Care, Toho University School of Medicine, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan, e-mail: foo@eb.mbn.or.jp, Fax: +81-3-3765-6518
[2] Department of Hematology, Toho University School of Medicine, Tokyo, Japan, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan
[3] Department of Radiology, Toho University School of Medicine, Tokyo, Japan, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan
[4] Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan

Received 12 July 2006; accepted 10 September 2006

Abstract. Gastro-esophageal reflux disease (GERD) is associated with a decreased salivary flow as well as gastric acid production. This study therefore aimed to investigate functional disorders of salivary glands in patients with GERD. *Methods:* Thirty-one consecutive patients with GERD underwent salivary gland scintigraphy. *Results:* If the results defined the optimal cutoff point for determining the decreased salivary secretion as 51% in parotid glands and 36% in submandibular glands, a decreased salivary secretion of right parotid gland, left parotid gland, right submandibular gland, and left submandibular gland was found in 39%, 32%, 36%, and 58%, respectively. Overall, salivary function disorder of at least one major salivary gland was found in 24 patients (78%) with GERD. There was no difference in the incidence of impaired salivary function between GERD patients with and without erosive esophagitis. Salivary gland function was more frequently diminished than expected in GERD. We concluded that the presence of impaired salivary gland function was considered to be one of risk factors for developing GERD symptoms.

Key words: Salivary scintigraphy; GERD; Washout ratio

Introduction

The major abnormalities associated with the development of GERD are related to incompetence of the antireflux barrier and impairment of esophageal luminal clearance after reflux [1, 2]. During esophageal acid clearance, salivation plays an important role in defending the esophageal mucosa [3, 4]. Esophageal clearance of regurgitated gastric contents is determined by three mechanisms: gravity, propulsive peristalsis, and salivary secretion [5]. The reduction of the majority of the reflux volume occurs within the first two swallows subsequent to a reflux event, with subsequent swallows producing an acid neutralization of the lining of the esophageal mucosa which eventually returns the mucosa to a pH above 4.0 [6]. Although saliva plays an important role in esophageal acid clearance, facilitation of acid clearance has only been addressed via work on various medications which have been shown to have prokinetic effects on the esophagus [7, 8]. Little attention has been paid to the role of salivation in esophageal clearance. On the other hand, salivary secretion is needed as soon as acidic gastric contents reflux into the esophagus. Immediate salivary response to gastro-esophageal is not evaluated by saliva collection methods. The aim of this study is to evaluate the salivary gland function by means of dynamic salivary scintigraphy and to assess correlation between salivary function disorders and developing GERD.

Patients and methods

Thirty-one consecutive patients (mean age 55 year old, male/female = 13/18) with GERD underwent salivary gland scintigraphy. GERD was diagnosed by endoscopy and gastro-esophageal reflux self-report questionnaires. As shown in Figure 1, erosive esophagitis was found in 14 of 31 patients with GERD symptoms, whereas the mucosal break of the esophagus was not detected in the remaining 17 patients. Of 14 patients with erosive esophagitis, 11 were classified into grade A according to the Los Angels classification. Three were classified into grade B and severe esophagitis, grade C or D, was not found in the present study. All of the patients were asked to refrain from drugs known to affect salivary secretion, such as anti-depressives, anti-psychotics and anti-hypertensives, which have an anti-cholinergic or anti-adrenergic action [9], for at least one week prior to salivary scintigraphy. Thirteen healthy volunteers (6 men, 7 women, average age 22.6 ± 4.9 years) were also enrolled to define the criteria of salivary dysfunction.

* *Corresponding author*



Fig. 1. Flow diagram of the study.

Salivary scintigraphy

After intravenous administration of 180 to 200 Mbq 99mTc-pertechnetate, imaging was begun immediately in order not to miss the initial portion of the curve from which parameters were obtained. A single-headed gamma camera was used with a high-resolution collimator and a symmetrical 20% window around a 140 keV photopeak. Anterior sequential imaging was performed every minute for 40 min. At 20 min after injection of radionuclide, a lemon candy was administrated intraorally to stimulate salivary secretion. Regions of Interests (ROI) were selected on the individual submandibular and parotid glands, oral cavity, and thyroid gland (Fig. 2). Time activity curves were drawn for each of these. A background area was selected in shoulder region. The salivary time activity curves were subjected to a two-step background subtraction protocol as follows. Time activity curve of background was normalized to the area of individual salivary gland and subtracted from individual organ curves to yield stage one subtracted curves.



Fig. 2. Time activity curves of two parotid glands.



Fig. 3. Washout rates of 13 healthy volunteers in each four major salivary gland.



Fig. 4. A representative time-activity curve generated from salivary scintigraphy in patients with grade B reflux esophagitis.

Washout ratio was defined as the following formula; peak count before lemon candy administration-lowest count after administration/ peak count before administration. Washout ratios represent the function of saliva excretion of the major salivary glands. They were also asked to abstain from swallowing, chewing, sucking or any other mechanical stimulation of salivary flow.

Results

As shown in Figure 3, the washout ratios of parotid glands were higher than those of submandibular glands in healthy volunteers. The washout ratio was 60.8 ± 10.7 % in right parotid gland. 62.0 ± 10.1 % in left parotid gland. 48.2 ± 14.0 % in right submandibular gland, and 52.8 ± 14.3 % in left submandibular gland. Since the overall washout ratio was 61.3 ± 10.2 % in parotid glands and 50.5 ± 14.1 % in submandibular glands, the results defined the optimal cutoff point for determining the decreased salivary secretion (mean-SD) as 51 % and 36 %, respectively. Figure 4 demonstrates reduced washout ratios of all major salivary glands in 65-year-old patient with grade B reflux esophagitis.

Results of salivary scintigraphy in 31 GERD patients were demonstrated in Table 1. The mean washout ratio of GERD patients was 55.8 % in the right parotid gland, 57.0 % in the left parotid gland, 53.5 % in the right submandibular gland. and 46.9 % in the left submandibular gland. According to the above-mentioned cutoff points, a decreased salivary secretion was found in 12 (39 %) in the right parotid gland, 10 (32 %) in the left parotid gland, 11 (36 %) in the right submandibular gland, and 18 cases (58 %)in the left submandibular gland.

Overall, salivary function disorder of at least one major salivary gland was found in 24 patients (78 %) with GERD. Ten of 14 patients (71 %) with reflux esophagitis and 14 of 17 patients (82 %) without reflux esophagitis had decreased salivary excretion after stimulation. There was no difference in the incidence of impaired salivary function between GERD patients with and without erosive esophagitis.

Discussion

Esophageal acid clearance consists of two processes: after reflux, most acid volume is cleared by esophageal peristalsis and gravity leaving only a minimal residue that sustains an acidic pH in the esophageal mucosa until it is neutralized by swallowed saliva 6 [10]. Salivary volume has been reported to be lower in patients with reflux esophagitis than in normal controls [3, 8]. Reduction in salivary function has been considered in the pathogenesis of reflux esophagitis. In the present study, salivary function disorder of at least one major salivary gland was found in 78 % of patients with GERD. There was no difference in the incidence of impaired salivary function between GERD patients with and without erosive esophagitis.

The aim of the present study was to test whether patients with GERD symptoms suffer from impaired salivary secretion. Chronic salivary dysfunction is clinically significant because it may lead to rampant dental destruction, mucosal infection and a variety of speech and digestive disturbances, and in itself may seriously impair the patient's quality of life [11, 12]. It has frequently been shown that salivary secretions decrease with age, the age-related decline being more

Table 1. Results of salivary scintigraphy in 31 GERD patients.

Age	Gender	diagnosis	grade	washout ratio			
				right PG	left PG	right SMG	left SMG
26	M	EE	A	49	50	8	30
27	F	EE	A	49	51	100	100
32	M	EE	A	20	20	10	10
33	F	EE	A	76	76	44	45
35	M	EE	A	65	57	77	79
37	M	EE	A	62	74	84	89
48	M	EE	A	61	65	38	39
56	M	EE	A	22	35	35	35
69	F	EE	A	49	62	62	61
70	F	EE	A	62	51	66	72
70	F	EE	A	66	72	70	71
38	F	EE	B	50	63	37	31
28	M	EE	B	63	67	47	48
49	M	EE	B	80	80	70	68
56	M	NERD	M	80	65	50	50
57	F	NERD	M	0	0	5	0
58	F	NERD	M	40	40	35	35
58	F	NERD	M	65	66	63	63
59	F	NERD	M	80	80	67	48
61	M	NERD	M	49	25	60	60
63	F	NERD	M	40	25	26	30
69	F	NERD	M	44	48	54	53
71	M	NERD	M	45	68	65	0
73	F	NERD	M	65	72	86	86
76	M	NERD	M	59	65	65	45
85	M	NERD	M	67	67	51	47
48	F	NERD	M	75	73	55	40
57	M	NERD	M	53	40	10	10
41	F	NERD	M	93	92	43	43
54	F	NERD	M	47	48	39	45
55	F	NERD	M	80	80	70	60

EE: erosive esophagitis, NERD: non-erosive reflux dosease, PG: parotid gland, SMG: submandibular gland

marked in women and than in men [13]. Since the prevalence of GERD increased with age and was higher than in males in the elderly, the development of reflux esophagitis could be favored by the age related loss of the salivary response to acidic gastroesophageal reflux.

A method for measuring the flow of whole salivary gland in which we ask each participant to spit into a pre-weighed collection tube once each minute for 3 min is unable to evaluate each salivary gland separately [14]. In contrast, scintigraphy has been used to quantify the uptake and the secretion in individual salivary glands. It has been reported that of the total salivary secretion of 1.5 L/day approximately 75% is secreted by the submandibular glands, 20% by the parotid glands and the rest by sublingual and other salivary glands [15]. Therefore, a volume of salivary secretion should differ between patients with impaired salivary glands and those with impaired submandibular glands.

The parotid gland predominantly secretes a protein rich saliva which includes enzymes like amylase while the submandibular secretions are mucin rich which are useful in lubricating the bolus of food [16]. It has been also reported that submandibular glands showed a greater tendency towards profuse unstimulated secretions [17]. These suggest that GERD symptoms caused by impaired salivary secretion may differ widely. It is desirable to evaluate individual salivary gland function separately.

Salivary flow is increased during esophageal acid perfusion, and saliva may act as an endogeneous antacid to protect against symptomatic gastroesophageal reflux [4]. Normal salivary secretion decreases the time that acid is in contact with the esophageal mucosa. The buffering ability of saliva is supplied mainly by bicarbonate [18]. Decreased salivary secretion results in decreased bicarbonate concentration and, therefore, insufficient acid neutralization. Since salivary gland function was frequently diminished in patients with GERD in the present study, decreased saliva seems to have an important role in developing GERD.

Several investigators have demonstrated the impairment of the salivary epidermal growth factor secretory response to mechanical and chemical stimulation of the esophagus in patients with GERD [19–21]. Epidermal growth factor is thought to play an important role in the repair of damaged esophageal mucosa. Furthermore, alterations in the salivary electrolytic composition can influence the protective capacity of the regional mucous membrane [17, 22]. It has been also reported that the pH and volume of saliva can have a clear correlation with some of the symptoms of patients with laryngo-pharyngeal reflux [23]. Costa et al. [24] have also shown the direct correlation between salivary volume and proximal episode of reflux on the esophageal pH-metry. Therefore, it is more desirable that not only volume of saliva but also composition of saliva is evaluated at the same time in GERD patients. Salivary scintigraphy is relatively safe, well tolerated, and easy to perform, and enables an assessment of the function of all major salivary glands individually. Although it can easily assess the salivary secretion in a short time, further studies should be carried out to evaluate the correlation between washout ratios and composition of saliva. We concluded that the presence of impaired salivary gland function was considered to be one of risk factors for developing GERD symptoms.

References

[1] Dodds, W. J., Dent, J., Hogan W. J. *et al.* (1982). Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. *N. Engl. J. Med.* 25, 1547–52.
[2] Pope, C. E (1994). Acid-reflux disorders. *N. Engl. J. Med.* 331, 656–60.
[3] Kao, C. H., Ho, Y. J., ChangLai, S. P. *et al.* (1999). Evidence for decreased salivary function in patients with reflux esophagitis. *Digestion* 60, 191–5.
[4] Helm, J. F., Dodds, W. J., Hogan, W. J. (1987). Salivary response to esophageal acid in normal subjects and patients with reflux esophagitis. *Gastroenterology* 93, 1393–7.
[5] Dodds, W. J., Hogan, W. J., Helm, J. F. *et al.* (1981). Pathogenesis of reflux esophagitis. *Gastroenterology* 81: 376–94.

[6] Helms, J. F., Dodds, W. J., Pelc, L. R. *et al.* (1984). Effect of esophageal emptying and saliva on clearance of acid from the esophagus. *N. Engl. J. Med.* **310**, 284–8.
[7] Toussaint, J., Goussin, A., Deruyttere, M. (1991). Healing and prevention of relapse of reflux esophagitis by cisapride. *Gut* **32**: 1280–5.
[8] Sonnenberg, A., Steinkamp, U., Weise, A. *et al.* (1982). Salivary secretion in reflux esophagitis. *Gastroenterology* **83**: 889–95.
[9] Vissink, A., van Nieuw Amerongen, A., Wesseling, H. *et al.* (1992). Dry mouth: possible cause-pharmaceuticals. *Ned. Tijdschr. Tandheelkd.* **99**: 103–12.
[10] Helms, J. F., Dodds, W. J., Riedel, D. R. *et al.* (1994). Determinants of esophageal acid clearance in normal subjects. *Gastroenterology* **85**, 607–612.
[11] Sreebny, L. M. (2000). Saliva in health and disease: an appraisal and update. *Int. Dent. J.* **50**, 140–61.
[12] Sreebny, L. M., Valdini, A. (1987). Xerostomia. A neglected symptom. *Arch. Intern. Med.* **147**, 1333–7.
[13] Furukawa, N., Iwakiri, R., Koyama, T., *et al.* (1999). Proportion of reflux esophagitis in 6010 Japanese adults-prospective evaluation by endoscopy. *J. Gastroenterol.* **34**, 441–4.
[14] Shern, R. J., Fox, P. C., Cain, J. L. *et al.* (1990). A method for measuring the flow of saliva from the minor salivary glands. *J. Dent. Res.* **69**, 1146–9.
[15] Ganong, W. F. (1967). Ch 26 Gastro-intestinal motility and secretion, in: *Review of Medical Physiology*, 3rd edition, California, Lange Medical Publications, pp. 391–413.
[16] Malpani, B. L., Samuel, A. M., Ray, S. (1995). Differential kinetics of Parotid and Submandibular gland function as demonstrated by scintigraphic means and its possible implications. *Nucl. Med. Commun.* **16**, 706–9.
[17] Namiot, Z., Rourk, R. M., Piascik, R. *et al.* (1994). Interrelationship between esophageal challenge with mechanical and chemical stimuli and salivary protective mechanisms. *Am. J. Gastroenterol.* **89**, 581–7.
[18] Helm, J. F., Dodds, W. J., Hogen, W. J. et al. (1982). Acid-neutralizing capacity of human saliva. *Gastroenterology* **83**, 69–74.
[19] Rourk, R. M., Namiot, Z., Edmunds, M. C. *et al.* (1994). Diminished luminal release of esophageal epidermal growth factor in patients with reflux esophagitis. *Am. J. Gastroenterol.* **89**, 1177–84.
[20] Li, L., Yu, Z., Piascik, R. *et al.* (1993). Effect of esophageal intraluminal mechanical and chemical stressors on salivary epidermal growth factor in humans. *Am. J. Gastroenterol.* **88**, 1749–55.
[21] Sarosiek, J., Scheurich, C. J., Marcinkiewicz, M. *et al.* (1996). Enhancement of salivary esophagoprotection: rationale for a physiological approach to gastroesophageal reflux disease. *Gastroenterology* **110**, 675–81.
[22] Gray, M. R., Donnelly, R. J., Kingsnorth, A. N. (1991). Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus. Br. J. Surg. **78**, 1461–6.
[23] Costa, H. O., Eckley, C. A. (2004). Correlation between salivary pH and volume and laryngopharyngeal symptoms. *Rev. Bras. Otorinol.* **70**, 19–24.
[24] Costa, H. O., Neto, O. M., Eckley, C. A. (2005). Is there a relationship between the pH and volume of saliva and esophageal pH-metry results? *Dysphagia* **20**, 175–81.

Histol Histopathol (2007) 22: 641-649

http://www.hh.um.es

Histology and Histopathology

Cellular and Molecular Biology

Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers

N. Hirano[1,2], T. Tsukamoto[1], T. Mizoshita[1], C. Koriyama[3], S. Akiba[3], F. Campos[3], G. Carrasquilla[4], E. Carrascal[5], X. Cao[1], T. Toyoda[1], H. Ban[1], K. Miki[2] and M. Tatematsu[1]

[1]Division of Oncological Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan, [2]Division of Gastroenterology and Hepatology, Department of Internal Medicine (Ohmori) School of Medicine, Faculty of Medicine, Toho Unviersity, Tokyo, Japan, [3]Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, [4]Department of Microbiology, Faculty of Health Sciences, Universidad del Valle, San Fernando, Cali, Colombia and [5]Department of Pathology, Faculty of Health Sciences, Universidad del Valle, San Fernando, Cali, Colombia

Summary. Aims: We have previously demonstrated the importance of gastric and intestinal phenotypic expression for stomach carcinogenesis. In this study, we focused on Epstein-Barr virus (EBV)-associated stomach cancers, with special attention to Cdx2.

Methods and Results: We evaluated the expression of gastric and intestinal phenotypic markers by immunohistochemistry in 35 EBV-positive [EBV (+)] and 75 EBV-negative [EBV (-)] stomach cancers in Colombia. The lesions were divided phenotypically into gastric (G), gastric-and-intestinal mixed (GI), intestinal (I), and null (N) phenotypes. In the EBV (+) cases, the lesions were divided phenotypically into 9 G (25.7%), 1 GI (2.9%), 3 I (8.6%), and 22 N (62.9%) types. Similarly, the EBV (-) lesions were also classified phenotypically as 15 G (20.0%), 19 GI (25.3%), 24 I (32.0%), and 17 N (22.7%) types. The proportion of N type EBV (+) lesions was higher than for their EBV (-) counterparts (P<0.0001). The expression of Cdx2 and MUC2 was also found to be significantly lower in EBV (+) than in EBV (-) stomach cancers (P=0.0001; P<0.0001). Cdx2 expression in the intestinal metaplastic glands present in non-neoplastic mucosa surrounding EBV (+) lesions was also significantly lower than in EBV (-) tumors (P=0.016) despite no evidence of EBV infection.

Conclusions. EBV (+) stomach cancers are characterized by low expression of intestinal phenotype markers, including Cdx2, and only occasional gastric phenotypic expression.

Offprint requests to: Tetsuya Tsukamoto, M.D., Ph.D., Division of Oncological Pathology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. e-mail: ttsukamt@aichi-cc.jp

Key words: Stomach cancer, Epstein-Barr virus, N type, Cdx2, MUC2

Introduction

Epstein-Barr virus (EBV) is a ubiquitous human herpes virus implicated in the etiology of many human malignancies, such as Burkitt's lymphoma (zur Hausen et al., 1970), nasopharyngeal carcinoma (Raab-Traub, 1992), Hodgkin's disease (Weiss et al., 1989), lymphoproliferative disorders in immunodeficiency patients (Hanto et al., 1981), and stomach cancer (Fukayama et al., 1998). EBV-associated stomach cancer account for about 10% of all gastric neoplasms (Shibata and Weiss, 1992; Tokunaga et al., 1993), although *Helicobacter pylori* (*H. pylori*) infection is a more important factor for stomach carcinogenesis. There are differences in the proportions of EBV-associated stomach cancers from country to country (Takada, 2000), and the rate in Colombia is significantly higher than in places with heavy gastric cancer burdens, such as Japan, China and Korea (Carrascal et al., 2003). The lesions due to EBV infection resemble nasopharyngeal lymphoepitheliomas and are named lymphoepithelioma-like carcinomas, and specific antigens such as EBV-determined nuclear antigen-1 (EBNA-1) and EBV-encoded small RNA-1 (EBER-1) point to the presence of the virus (Burke et al., 1990; Yanai et al., 1997a,b). Stomach cancers associated with EBV infection were more common in the upper stomach (cardia and fundus), and histologically are most often of undifferentiated type (Yanai et al., 1997). Each EBV-associated stomach cancer appears of monoclonal origin arising from a single EBV-infected cell (Imai et al., 1994). However, there are many obscure points with regard to the

relations between EBV infection and stomach carcinogenesis.

Gastric and intestinal phenotypic expression is important for the histogenesis of stomach cancer (Tatematsu et al., 2003). Several reports have indicated that it is possible to analyze the phenotypic expression of each gastric cancer cell using gastric and intestinal epithelial cell markers (Egashira et al., 1999; Kawachi et al., 2003; Mizoshita et al., 2003; Tsukamoto et al., 2005). Thus, division into gastric (G), gastric-and-intestinal mixed (GI), intestinal (I), and null (N) phenotypes is possible, independent of the histological classification (Tajima et al., 2001; Tatematsu et al., 2003; Inada et al., 2004; Mizoshita et al., 2004a). However, the relation between EBV infection and phenotypic expression has yet to be clarified in detail in stomach cancers associated with the virus. Several authors have demonstrated a correlation between EBV infection and phenotypic marker expression (Lee et al., 2004; Nakamura et al., 2005), but concrete conclusions have yet to be drawn.

In the present study, we therefore evaluated the expression of gastric and intestinal phenotypic markers by immunohistochemistry in 110 stomach cancers in Colombia, along with adjacent non-neoplastic mucosa. The EBV infection status was also evaluated by in situ hybridization in these lesions.

Materials and methods

Samples and tissue collections

The study subjects were stomach carcinoma patients newly diagnosed during the period between September 2000 and June 2003 in the following four reference hospitals in Colombia: Instituto de los Seguros Sociales "Rafael Uribe Uribe", Hospital Universitario del Valle, Hospital San Juan de Dios in Cali, and Instituto Nacional de Cancerologia in Bogota. We examined EBER-1 expression among formalin-fixed paraffin-embedded blocks of 368 cases with gastric carcinomas, and found that 42 cases were positive (Koriyama et al., manuscript submitted). We selected paraffin-embedded blocks of 35 cases with gastric carcinomas, mainly surgically resected tumors, for the present analysis. Seventy-five EBER-1-negative cases were selected matched for gender, age (5-year category), histology [differentiated (well and moderately differentiated) and undifferentiated (poorly differentiated and signet-ring cell) types in majority area], and area (Bogota or Cali) (Table 1). The Institutional Review Board of the Faculty of Health, Universidad del Valle, Cali, Colombia, approved this study and all subjects gave informed consent.

The patient group comprised 84 men and 26 women, aged 59.0±12.5 years (mean ± standard deviation). All specimens were fixed in 10% buffered formalin. Classification was made according to the Japanese Classification of Gastric Carcinomas (Japanese Gastric Cancer Association, 1998) in spite of widely used Lauren's classification (Lauren, 1965), which is inadequate for the studies of histogenesis of stomach cancers and phenotypic expression at the cellular level, because it confuses intestinal phenotypic cancer cells with "diffuse" structure and gastric phenotypes with the "intestinal" (glandular or tubular) morphology. Carcinomas with adjacent non-neoplastic mucosa were serially cut into 5-mm slices in parallel with the lesser curvature and embedded in paraffin, and then sectioned and stained with hematoxylin-eosin (HE) for histological examination.

In situ hybridization of EBER-1

EBER-1 *in situ* hybridization was performed with a kit according to the manufacturer's instructions (Dako, Glostrup, Denmark). Paraffin sections 4 μm thick were deparaffinized, rehydrated, predigested with proteinase K for 15 min at room temperature and hybridized with a fluorescein-conjugated EBV oligonucleotide probe (EBER PNA Probe/Fluorescein) for 90 min at 55°C. After washing with 0.1M TBS (pH 10) for 25 min at 55°C, hybridization signals were detected by serial incubation with anti-fluorescein isothiocyanate rabbit polyclonal antibody (Anti-FITC/AP), and then with biotinylated Mouse IgG as secondary antibody, followed by the avidin biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA, USA). Finally, immune complexes were visualized by incubation with 0.01% H_2O_2 and 0.05% 3,3'-diaminobenzidine tetrachloride (DAB). Nuclear counterstaining was accomplished with Mayer's hematoxylin. From the results, EBER-positive and EBER-negative lesions were defined as EBV-positive [EBV (+)] and EBV-negative [EBV (-)](Fukayama et al., 2001).

Histological and immunohistochemical examination

Immunohistochemical staining was carried out with monoclonal antibodies against the following antigens:

Table 1. Correlations between clinicopathologic findings and EBV infection in 110 stomach cancers.

Clinicopathologic findings	EBV (+) (n=35)	EBV (-) (n=75)	P-value
Age			
Years (mean±SD)	58.9±13.6	59.1±12.0	P=0.88
Sex			
Male(n=84)	28	56	P=0.63
Female(n=26)	7	19	
Histological classification [a]			
Differentiated type (n=44)	13	31	P=0.835
Undifferentiated type (n=66)	22	44	

SD: standard deviation. [a]: Classified based on structure of elements. "Differentiated type" includes tubular and papillary types, whereas "Undifferentiated type" consists of signet-ring cell and poorly differentiated types.

MUC5AC (CLH2, 1:500; Novocastra Laboratories, Newcastle upon Tyne, UK); MUC6 (CLH5, 1:500; Novocastra Laboratories); MUC2 (Ccp58, 1:500; Novocastra Laboratories); villin (12, 1:20,000; Transduction Laboratories, Lexington, KY, USA); and Cdx2 (Caudal-related homeobox gene 2) (CDX2-88, 1:100; BioGenex, San Ramon, CA, USA).

For gastric and intestinal phenotypic markers, we used normal gastric mucosa and ileum as controls. The precise procedures for immunohistochemical techniques were as previously described (Tatematsu et al., 2003; Mizoshita et al., 2003, 2004b; Tsukamoto et al., 2005). Briefly, 4 μm-thick consecutive sections were deparaffinized and hydrated through a graded series of alcohols. After inhibition of endogenous peroxidase activity by immersion in 3% H_2O_2/methanol solution, antigen retrieval was conducted for detection of binding of the above-mentioned antibodies with 10 mM citrate buffer, pH 6.0, in a microwave oven for 10 min at 98°C. Sections were incubated with primary antibodies, thoroughly washed in phosphate-buffered saline (PBS), then incubated with biotinylated secondary antibody, followed by the avidin biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA, USA). Finally, immune complexes were visualized by incubation with 0.01% H_2O_2 and 0.05% DAB. Nuclear counterstaining was accomplished with Mayer's hematoxylin.

Three independent pathologists (N.H., T.M., and T.T.) judged the histology and immunohistochemical staining for the phenotypic markers and Cdx2. Reactivity for the phenotypic markers and Cdx2 was scored according to the percentage of positively stained tumor cells in the section areas on a 4-point-scale: score 0, <10%; score 1, 10-33%; score 2, 34-66%; score 3, 67-100%. A result was considered positive (+) with a score of 1 or more.

Phenotypic classification of cancers

The phenotypes of stomach cancer cells were determined using two gastric (MUC5AC and MUC6) and two intestinal (villin and MUC2) phenotypic markers. The decisions as to the phenotypes of stomach cancerous areas in which 10% or more of the section area consisted of at least one gastric or intestinal epithelial cell phenotype were classified as gastric (G type) or intestinal (I type) phenotype cancers, respectively. Those which showed both gastric and intestinal phenotypes were classified as gastric and intestinal mixed phenotype (GI type) cancers, while those showing neither gastric nor intestinal phenotype expression were grouped as unclassified (N type) (Tatematsu et al., 2003; Mizoshita et al., 2003; Tsukamoto et al., 2005).

Evaluation of the background gastritis of stomach cancer

Inflammatory response in non-neoplastic surrounding mucosa [of 26 EBV (+) and 57 EBV (-) stomach cancers] were scored according to the Updated Sydney System (Dixon et al., 1996). The degree of gastric mucosal inflammation including mononuclear cell infiltration, neutrophils infiltration, glandular atrophy, and intestinal metaplasia were classified into four grades as follows: 0 = none, 1 = mild, 2 = moderate and 3 = marked.

Expression of gastric and intestinal phenotypic markers and Cdx2 in intestinal metaplastic glands in non-neoplastic surrounding mucosa of EBV (+) and EBV (-) stomach cancers

Intestinal metaplastic glands were observed in non-neoplastic surrounding mucosa of 9 EBV (+) and 26 EBV (-) stomach cancers. The expression of gastric and intestinal phenotypic markers and Cdx2 was also evaluated in intestinal metaplastic glands of both EBV (+) and EBV (-) cases (Mizoshita et al., 2004b, Tatematsu et al., 2005). Reactivity for the phenotypic markers and Cdx2 was scored according to the percentage of positively stained epithelial cells in the intestinal metaplastic glands on a 4-point-scale: score 0, <10%; score 1, 10-33%; score 2, 34-66%; score 3, 67-100%.

Statistical analysis

The data were analyzed by the Fisher's exact test, c2 test or Mann-Whitney U test for differences between EBV (+) and EBV (-) groups. P-values <0.05 were considered as statistically significant.

Results

Relations between EBV infection and expression of gastric and intestinal phenotypic markers, and Cdx2, in stomach cancers

Data for comparisons between EBV (+) and EBV (-) lesions for phenotypic marker and Cdx2 expression in cancerous tissues are summarized in Table 2. The average scores for MUC2 and Cdx2 expression were significantly lower in EBV (+) than in EBV (-) cases ($P<0.0001$ and $P=0.0001$, respectively), independently of whether differentiated ($P<0.005$ and $P<0.02$, respectively) or undifferentiated ($P<0.01$ and $P<0.005$, respectively). Regarding the other phenotypic markers, there were no significant differences between the two groups.

Comparison of phenotypes between EBV (+) and EBV (-) stomach cancers

Data for comparisons between EBV (+) and EBV (-) lesions are summarized in Table 3. In the EBV (+) cases, the lesions were divided phenotypically into 9 G (25.7%), 1 GI (2.9%), 3 I (8.6%), and 22 N (62.9%) types. Similarly, the EBV (-) lesions were also classified phenotypically as 15 G (20.0%), 19 GI (25.3%), 24 I

(32.0%), and 17 N (22.7%) types. There was a significant difference in the proportions of each phenotype between EBV (+) and EBV (-) lesions (P<0.0001).

Comparison of phenotypic markers in differentiated and undifferentiated regions in EBV (+) and EBV (-) stomach cancer cases

To further analyze the expression of gastric and intestinal phenotypic markers, the phenotypes were compared in mixed structure cases containing differentiated and undifferentiated regions (Table 4). Six EBV (+) cases consisted of 2 adenocarcinomas with differentiated predominance and 4 tumors with larger undifferentiated areas. Among them, 3 cases lacked the phenotypic markers in the undifferentiated regions (3/6=50%). For EBV (-) cases, 2 cases were differentiated region dominant and 7 were undifferentiated predominant, none of them lost the

Table 2. Correlations between EBV infection and the expression of the phenotypic markers, and Cdx2 in the stomach cancer cases.

	The average scores of each marker[a]				
	MUC5AC	MUC6	MUC2	villin	Cdx2
EBV (+) (n=35)	0.51±0.16	0.029±0.029	0.057±0.040	0.086±0.063	0.20±0.099
Differentiated (n=13)	0.615±0.266	0.077±0.077	0.077±0.077	0.231±0.166	0.231±0.166
Undifferentiated (n=22)	0.455±0.194	0±0	0.045±0.045	0±0	0.182±0.125
EBV (-) (n=75)	1.013±0.15	0.16±0.063	1.033±0.13	0.23±0.070	1.060±0.13
Differentiated (n=31)	1.000±0.2236	0.226±0.101	0.903±0.169	0.484±0.153	1.355±0.2
Undifferentiated (n=44)	1.023±0.191	0.114±0.081	1.125±0.166	0.045±0.032	0.852±0.156
P-values between EBV (+) and (-) cases [b]	P= 0.098	P= 0.58	P< 0.0001	P= 0.39	P= 0.0001
P-values between EBV (+) and (-) differentiated adenocarcinomas	NS	NS	P< 0.005	NS	P< 0.02
P-values between EBV (+) and (-) undifferentiated adenocarcinomas	NS	NS	P< 0.01	NS	P< 0.005

[a]: Each score is average ± standard error (SE); [b]: Each P-value is analyzed by Mann-Whitney U test. NS, not significant.

Table 3. The phenotype classification in EBV (+) and EBV (-) stomach cancers.

	Phenotypic classification[a]				
	G type	GI type	I type	N type	total
EBV (+) (n=35)	9 (25.7%)	1 (2.9%)	3 (8.6%)	22 (62.9%)	35 (100%)
Differentiated	3	1	2	7	13
Undifferentiated	6	0	1	15	22
EBV (-) (n=75)	15 (20.0%)	19 (25.3%)	24 (32.0%)	17 (22.7%)	75 (100%)
Differentiated	4	10	11	6	31
Undifferentiated	11	9	13	11	44
Total	24 (21.8%)	20 (18.2%)	27 (24.5%)	39 (35.5%)	110 (100%)

[a]: P< 0.0001 among G, GI, I , and N types between EBV (+) and (-) cases (χ^2 test).

Table 4. Correlation between EBV infection and the expression of the phenotypic markers, and Cdx2 in intestinal metaplasia.

	The average scores of each marker[a]				
	MUC5AC	MUC6	MUC2	villin	Cdx2
EBV (+) (n=9)	1.000±0.441	0	2.333±0.441	2.286±0.421	0.556±0.377
EBV (-) (n=26)	1.769±0.256	0.231±0.139	2.808±0.136	2.350±0.244	1.654±0.192
P-value[b]	P=0.15	P=0.61	P=0.50	P=0.80	P=0.016

[a]: Each score is average±standard error (SE); [b]: Each P-value is analyzed by Mann-Whitney U test.

phenotypic markers. Thus, EBV (+) carcinomas appeared to lose phenotypic markers during progression from differentiated to undifferentiated structure (P<0.02).

Relations between EBV infection and grading of gastritis surrounding non-neoplastic mucosa

Data for comparisons between EBV (+) and EBV (-) cases regarding the grade of gastritis surrounding non-neoplastic mucosa using Updated Sydney System are summarized in Table 5. The grades of mononuclear cell and neutrophil infiltration, mucosal glandular atrophy, and intestinal metaplasia showed no significant difference between the two groups.

Relations between EBV infection and expression of gastric and intestinal phenotypic markers, and Cdx2 in intestinal metaplastic glands

Data for comparisons between EBV (+) and EBV (-) cases regarding phenotypic marker and Cdx2 expression in intestinal metaplastic glands are summarized in Table 6 (Fig. 3). The average score for Cdx2 expression was significantly lower in EBV (+) than in EBV (-) cases (P=0.016). Regarding the other phenotypic markers, there were no significant differences between the two groups.

Discussion

Cdx2 is important for the maintenance of intestinal phenotypic expression not only in the normal small and large intestine (Silberg et al., 2000), but also in intestinal metaplasia (Mizoshita et al., 2001; Almeida et al., 2003; Tsukamoto et al., 2004) and carcinomas of the stomach (Almeida et al., 2003; Mizoshita et al., 2003). Cdx2 nuclear expression can be detected in approximately half of advanced stomach cancers (Mizoshita et al., 2003) and about 80% of early lesions (Mizoshita et al., 2004a,b). Many stomach cancers have expression of genes associated with induction and maintenance of the differentiation of small and large intestine, such as Cdx2 and Cdx1 (Chen et al., 2003). However, our present data provide clear evidence that Cdx2 expression is less frequent in EBV (+) than in EBV (-) stomach cancers.

Table 5. Correlation between EBV infection and status of surrounding non-neoplastic mucosa.

	The average grades in surrounding mucosa[a]			
	Neutrophils	Mononuclear Cells	Atrophy	Intestinal Metaplasia
EBV (+) stomach cancer (n=26)	1.154±0.107	1.692±0.173	1.154±0.120	0.577±0.173
EBV (-) stomach cancer (n=57)	1.175±0.087	1.474±0.118	1.140±0.088	0.720±0.120
P-values[b]	P=0.914	P=0.324	P=0.879	P=0.504

[a]: Each score is average±standard error (SE) for Updated Sydney System; [b]: Each *P*-value is analyzed by Mann-Whitney U test.



Fig. 1. An EBV (+) stomach cancer. **A.** HE staining. **B.** Note the lack of Cdx2 nuclear staining in the cancer cells. **C.** No MUC2 expression is detected in the cytoplasm of tumor cells. **D.** MUC5AC is present in the cytoplasm of normal gastric foveolar epithelium (red arrow), but not cancer cells. **E.** No MUC6 expression is apparent in the cytoplasm of tumor cells. **F.** EBER-1 is positive in the nuclei of cancer cells, but not normal gastric foveolar epithelium (arrow). x 200; EBER-1, EBV-encoded small RNA-1.